Cerivastatin-induced rhabdomyolysis: 11 case reports
Related Experiment Videos
Susan L Ravnan1, Christy Locke, William P Yee
1University of the Pacific Thomas J. Long School of Pharmacy and Health Sciences, Stockton, California, USA. sravnan@chw.edu
Abstract:
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are a frequently prescribed class of drugs that are generally well tolerated by most patients. A rare, yet serious side effect associated with these drugs is rhabdomyolysis. Although all HMG-CoA reductase inhibitors can cause this adverse effect, prevalence may differ among specific agents. Over a 16-month period, in three hospitals, 11 patients experienced cerivastatin-induced rhabdomyolysis, but no cases of rhabdomyolysis associated with any other HMG-CoA reductase inhibitors were reported.
Related Concept Videos
Drug Toxicity: Risk factors
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Toxicity: Dose-Dependent Reactions
Viral Hepatitis I: Introduction